Literature DB >> 6673050

Selected bacterial antibodies in Crohn's disease and ulcerative colitis.

I O Auer, A Röder, F Wensinck, J P van de Merwe, H Schmidt.   

Abstract

Agglutinins to four strains of anaerobic gram-positive coccoid rods (species of Eubacterium, Peptostreptococcus and Coprococcus) were found in significantly higher frequency in Crohn's disease (CD) than in ulcerative colitis (UC) and in other diseased control subjects and were virtually absent in apparently healthy subjects. When the posterior probability of having CD was calculated on the basis of these agglutination reactions, 64% of patients with CD and 34% of patients with UC but only 10% of diseased controls and none of the healthy controls were regarded as 'probable' or 'definite' cases of CD. However, the posterior probability of CD did not sharply differentiate between CD and UC but indicated chronic inflammatory bowel disease. Factors contributing to the appearance of these agglutinins in CD were also evaluated. The findings would indicate the importance of a damaged intestinal mucosal barrier for the production of these agglutinins, provided the antigens are present in the intestine. No significant differences were observed between the occurrence of antibodies to pseudomonas-like organisms (PLO) in CD and the various control groups. The study could not add further evidence to the hypothesis of a possible aetiopathogenic role of PLO in CD.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6673050     DOI: 10.3109/00365528309181586

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  22 in total

1.  Beneficial effects of glycocholic acid (GCA) on gut mucosal damage in bile duct ligated rats.

Authors:  B K Oktar; M A Gülpinar; F Ercan; A Cingi; I Alican; B C Yegen
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

2.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 3.  Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease.

Authors:  J P Ibbotson; J R Lowes
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

4.  Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues.

Authors:  R S Walmsley; A Anthony; R Sim; R E Pounder; A J Wakefield
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

Review 5.  Immunopathology of human inflammatory bowel disease.

Authors:  P Brandtzaeg; G Haraldsen; J Rugtveit
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Antibiotic Treatment Induces Long-lasting Changes in the Fecal Microbiota that Protect Against Colitis.

Authors:  Naomi L Ward; Caleb D Phillips; Deanna D Nguyen; Nanda Kumar N Shanmugam; Yan Song; Richard Hodin; Hai Ning Shi; Bobby J Cherayil; Allan M Goldstein
Journal:  Inflamm Bowel Dis       Date:  2016-10       Impact factor: 5.325

7.  Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.

Authors:  H C Rath; H H Herfarth; J S Ikeda; W B Grenther; T E Hamm; E Balish; J D Taurog; R E Hammer; K H Wilson; R B Sartor
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

Review 8.  The aetiology of Crohn's disease.

Authors:  G N Tytgat; C J Mulder
Journal:  Int J Colorectal Dis       Date:  1986-07       Impact factor: 2.571

9.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Location of acyl groups of trehalose-containing lipooligosaccharides of mycobacteria.

Authors:  R T Camphausen; M McNeil; I Jardine; P J Brennan
Journal:  J Bacteriol       Date:  1987-12       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.